360
Participants
Start Date
November 30, 2010
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
Placebo
Placebo administered twice per day for six weeks.
CX157 (TriRima)
One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
Eastside Comprehensive Medical Center, New York
Introspect of Buxmont, Ltd, Colmar
Richard H. Weisler, M.D. and Associates, Raleigh
Nathan Shapira, MD, Ph.D, Smyrna
Atlanta Institute of Medicine and Research, Atlanta
Clinical Neuroscience Solutions, Inc., Jacksonville
Kolin Research Group, Winter Park
Clinical Neuroscience Solutions, Inc., Orlando
The Segal Institute of Clinical Research, North Miami
University of South Florida College of Medicine Psychiatry Center, Tampa
Stedman Clinical Trials, Tampa
Gulfcoast Clinical Research Center, Fort Myers
Clinical Neurosciences Solutions, Inc., Memphis
NorthCoast Clinical Trials, Inc., Beachwood
North Star Medical Research, LLC, Middleburg Heights
Patient Priority Clinical Sites, LLC, Cincinnati
Northbrooke Research Center, Deer Brown
FutureSearch Trials of Dallas, Dallas
Community Clinical Research, Inc., Austin
Radiant Research, Murray
Synergy Clinical Research Center, National City
Synergy Escondido, Escondido
Excell Research, Oceanside
Pacific Clinical Research, Orange
Oregon Center for Clinical Investigations, Inc, Portland
Summitt Research Network (Oregon), Portland
Northwest Clinical Research Center, Bellevue
Summit Research Network (Seattle) LLC, Seattle
McLean Hospital, Belmont
AccelRx Research, Fall River
Lead Sponsor
CeNeRx BioPharma Inc.
INDUSTRY